A recent study identified RUNX2 as a potent prognostic factor in non-small cell lung cancer (NSCLC) patients, as RUNX2 expression was significantly correlated with NSCLC tumor progression and metastatic capability [47]. This evidence concerns the gene RUNX2 and neoplasm.